Deoxyschizandrin improved NAFLD through activating hepatic and central nervous system FXR/TGR5 signaling and enhancing leptin sensitivity (Gu et al., 2023). This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.